Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Intravenously Administered LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Conditions
Interventions
LP-284
Locations
4
United States
Cancer and Blood Specialists Clinic
Los Alamitos, California, United States
Florida Cancer Specialists
Lake Mary, Florida, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
START Mountain Region
West Valley City, Utah, United States
Start Date
January 3, 2023
Primary Completion Date
November 30, 2028
Completion Date
November 30, 2028
Last Updated
March 17, 2025
NCT07181681
NCT05919264
NCT06257264
NCT07360314
NCT07403721
NCT07539285
Lead Sponsor
Lantern Pharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions